AINS, inhibiteurs de la cyclo-oxygénase de type 2 et carcinogenèse pancréatique
Authors:
- Gaëtan Des GuetzGGGaëtan Des Guetz
- Robert BenamouzigRBRobert Benamouzig
- Stanislas ChaussadeSCStanislas Chaussade
- Jean-Luc BreauJBJean-Luc Breau
- 1 April 2005
- journal article
- review article
- Published by Elsevier in Gastroentérologie Clinique Et Biologique
- Vol. 29 (4) , 411-414
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?The Lancet Oncology, 2003
- Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical IssuesJNCI: Journal of the National Cancer Institute, 2002
- Expression of Inflammatory Modulator COX-2 in Pancreatic Ductal Adenocarcinoma and Its Relationship to Pathologic and Clinical ParametersAmerican Journal of Clinical Oncology, 2001
- Extent, mode, and dose dependence of anticancer effectsThe American Journal of Medicine, 2001
- Cyclooxygenase-2 in Carcinogenesis of the Gastrointestinal TractScandinavian Journal of Gastroenterology, 2001
- Immunohistochemical analysis of cyclooxygenase-2 expression in pancreatic tumorsJournal of Gastrointestinal Cancer, 1999
- Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinomaCancer, 1998
- Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.Journal of Clinical Oncology, 1997
- Suppression of Intestinal Polyposis in ApcΔ716 Knockout Mice by Inhibition of Cyclooxygenase 2 (COX-2)Cell, 1996
- Aspirin Use and the Risk for Colorectal Cancer and Adenoma in Male Health ProfessionalsAnnals of Internal Medicine, 1994